Rousselot secures global patents for joint health ingredient Colartix
Rousselot reveals the company has attained patents in Europe, Japan, and China for Colartix, its proprietary blend of collagen peptides and chondroitin sulfate developed for joint health applications. The ingredient is now patented under the title “Collagen hydrolysate composition for reducing joint pain after exercise.”
The filings are now listed at the European Patent Office (patent EP4465823B1), Japan Patent Office (patent JP7690140B2), and China National Intellectual Property Administration (patent CN118829360). Additional patent applications are under review in the United States and Brazil.
“These new patents are a milestone that underscores our commitment and ability to innovate in the collagen industry,” says Jeroen Colpaert, Rousselot’s EVP. “They not only provide exclusive protection to our Colartix customers but also strengthen their product appeal to consumers through association with proven innovation and trust.”
Supporting cartilage, mobility, and comfort
Scientific research has demonstrated Colartix’s efficacy in reducing joint discomfort across a range of ages, genders and activity levels. Since its launch in 2022, it has been incorporated into a variety of dietary supplements targeting both active individuals and those affected by aging or excess weight.
The ingredient has been shown to support joint and cartilage health, and is suited for high-protein supplements, functional foods, and sports nutrition, while also offering benefits beyond these categories.
According to Rousselot, the joint health supplements market reached US$4.4 billion in 2024 and is expected to grow by 2.4% annually through 2029. At the same time, Innova Market Insights’ data suggest that joint health supplement launches grew at an average annual rate of 4% from April 2020 to March 2025, with leading subcategories including hair, skin and nails, vitamins/minerals, and botanicals, and over half featuring skin or bone health claims.
Functional and versatile
The hydrolyzed cartilage matrix contains collagen peptides and glycosaminoglycans (GAGs), which the company highlights as unique due to its high content of type II collagen and chondroitin sulfate as the main GAG.
Designed for a daily 1 gm intake, Rousselot says Colartix is formulated for use in capsules, powders, tablets and functional shots, while its solubility and compatibility with other ingredients make the ingredient useful for a variety of convenient and functional applications.
